Search

Search Results

1. Altered modular organization of intrinsic brain functional networks in patients with Parkinson’s disease

   Although previous studies reported altered topology of brain functional networks in patients with Parkinson’s disease (PD), the modular organization...

   Qing Ma, Biao Huang, ... Ruiwang Huang in Brain Imaging and Behavior

   Article 10 February 2016
   

2. The relationships between mild cognitive impairment and phenotype in Parkinson’s disease

   Background:

   The concept of differing clinical phenotypes within Parkinson’s disease (PD) is well represented in the literature. However, there is no...

   Jennifer YY Szeto, Claire O’Callaghan, ... Simon JG Lewis in npj Parkinson's Disease

   Article Open access 27 August 2015

3. Targeting Therapeutics Across the Blood Brain Barrier (BBB), Prerequisite Towards Thrombolytic Therapy for Cerebrovascular Disorders—an Overview and Advancements

   Cerebral tissues possess highly selective and dynamic protection known as blood brain barrier (BBB) that regulates brain homeostasis and provides...

   K. K. Pulicherla, Mahendra Kumar Verma in AAPS PharmSciTech

   Article 23 January 2015
   

4. Antiparkinsonian Agents

   Parkinson disease, named after James Parkinson who first described the disorder in 1817, is a chronic, progressive neurologic disorder clinically...

   Steven J. Walsh, Kenneth D. Katz in Critical Care Toxicology

   Living reference work entry 2015
   

5. Anti-Parkinson Activity

   In humans, Parkinson’s disease is characterized by fixed facial expression, tremor at rest, slowing of voluntary movements, impaired gait, impaired...

   Mary-Jeanne Kallman in Drug Discovery and Evaluation: Pharmacological Assays

   Living reference work entry 2015
   

6. Synthesis and biological evaluation of quinolines, thiazolo[3,2-a]pyrimidines, thiadiazolo[3,2-a]pyrimidines and triazolo[3,4-b][1,3,4]thiadiazepines as antimicrobial agents

   Series of quinolines, thiazolo[3,2- a ]pyrimidines, thiadiazolo[3,2- a ]pyrimidines and triazolo[3,4- b ][1,3,4]thiadiazepines were synthesized by the...

   Seema Sahi, Satya Paul in Medicinal Chemistry Research

   Article 03 March 2016
   

7. Clinical risk factors associated with postoperative delirium and evaluation of delirium management and assessment team in lung and esophageal cancer patients

   Background

   Delirium is an acute change in cognition and concentration that complicates the postoperative course. Patients who suffer delirium after...

   Kiminaka Murakawa, Yoshihisa Kitamura, ... Toshiaki Sendo in Journal of Pharmaceutical Health Care and Sciences

   Article Open access 28 January 2015
   

8. Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study

   Background

   Despite the high use of antidepressants (ADs) among the elderly, there is limited information about the prescribing pattern of these drugs...

   Janet Sultana, Domenico Italiano, ... Gianluca Trifirò in European Journal of Clinical Pharmacology

   Article 15 January 2014
   

9. Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson’s Disease

   In the management of Parkinson’s disease, chronic L-DOPA therapy is associated with the development of motor fluctuations and dyskinesias. Since...

   Emmanuelle Pourcher, Robert A. Hauser in The Adenosinergic System

   Chapter 2015
   

10. Volume Transmission in Central Dopamine and Noradrenaline Neurons and Its Astroglial Targets

    Already in the 1960s the architecture and pharmacology of the brainstem dopamine (DA) and noradrenaline (NA) neurons with formation of vast numbers...

    Kjell Fuxe, Luigi F. Agnati, ... Dasiel O. Borroto-Escuela in Neurochemical Research

    Article 17 April 2015
    

11. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

    Introduction

    The efficacy of a cholinesterase inhibitor, donepezil, in patients with dementia with Lewy bodies (DLB) was investigated to confirm the...

    Manabu Ikeda, Etsuro Mori, ... Kenji Kosaka in Alzheimer's Research & Therapy

    Article Open access 03 February 2015
    

12. Potential Neuroprotective Activity of Ginseng in Parkinson’s Disease: A Review

    Parkinson’s disease is a chronic, multifactorial and progressive neurologic condition that affects around six million people worldwide, normally over...

    Elena González-Burgos, Carlos Fernandez-Moriano, M. Pilar Gómez-Serranillos in Journal of Neuroimmune Pharmacology

    Article 29 October 2014
    

13. An analysis of the involvement of monoaminergic mechanisms in the neuropsychotropic effects of neuroglutam

    It is known that neuroglutam (at 26 mg/kg) potentiates stereotypy that is induced by the agonist of postsynaptic dopamine receptors apomorphine (1...

    I. N. Tyurenkov, V. V. Bagmetova, ... G. I. Kovalev in Neurochemical Journal

    Article 01 January 2015

14. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN^TM) in subjects with clinically uncertain parkinsonian syndromes

    Introduction

    Diagnostic effectiveness of Ioflupane I 123 injection (DaTSCAN ^TM , DaTscan ^TM , or [123I]FP-CIT or ioflupane [ ¹²³ I]) SPECT imaging, was...

    Nin Bajaj, Robert A Hauser, ... Igor D Grachev in Alzheimer's Research & Therapy

    Article Open access 08 October 2014
    

15. Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy

    Purpose

    To evaluate the effect of a broad range of covariates on the survival of a real-life long-term follow-up cohort of community-dwelling patients...

    Concetta Rafaniello, Flavia Lombardo, ... Annalisa Capuano in European Journal of Clinical Pharmacology

    Article 22 October 2013
    

16. Adrenergic and Dopaminergic Modulation of Immunity in Multiple Sclerosis: Teaching Old Drugs New Tricks?

    Multiple sclerosis (MS) is an autoimmune disorder of the CNS characterized by inflammation, demyelination and axonal loss. Classical evidence in...

    Marco Cosentino, Franca Marino in Journal of Neuroimmune Pharmacology

    Article 17 October 2012
    

17. Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation

    Background

    Disorders of oxidative phosphorylation affects 1/5000 individuals and present heterogeneous involvement of tissues highly dependent upon...

    Monica Bandettini di Poggio, Claudia Nesti, ... Filippo M Santorelli in BMC Medical Genetics

    Article Open access 07 October 2013
    

18. Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson’s Disease, and Levodopa Efficacy

    Objectives

    We investigated the association between catechol-O-methyltransferase ( COMT ) gene polymorphisms and Parkinson’s disease (PD)...

    Bowen Yin, Yongqian Chen, Limei Zhang in Molecular Diagnosis & Therapy

    Article 15 November 2013
    

19. Gender and Polypharmacotherapy in the Elderly: A Clinical Challenge

    Polypharmacotherapy is a major concern in the elderly and especially in older women after the age of 80. It results from the intake of prescription...

    Christina Hofer-Dückelmann in Sex and Gender Differences in Pharmacology

    Chapter 2013
    

20. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011

    Background

    Reporting of adverse drug reactions (ADRs) has traditionally been the sole province of healthcare professionals. In the European Union,...

    Lise Aagaard, Ebba Holme Hansen in BMC Pharmacology and Toxicology

    Article Open access 13 June 2013